Author Question: Given a cash value policy with the following characteristics: face value = 200,000, cash value = ... (Read 43 times)

karlynnae

  • Hero Member
  • *****
  • Posts: 599
Given a cash value policy with the following characteristics: face value = 200,000, cash value = 50,000, outstanding loans = 10,000 and surrender charges = 1,000, the benefits payable at death are
 
  A)
 
  200,000.
  B)
 
  199,000.
  C)
 
  190,000.
  D)
 
  150,000.

Question 2

The EV/EBITDA model involves a two-step process: first estimating firm value or EV, then subtracting other claims (such as debt) in order to isolate the value of equity.
 
  Indicate whether the statement is true or false



lindahyatt42

  • Sr. Member
  • ****
  • Posts: 322
Answer to Question 1

C

Answer to Question 2

TRUE



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

On average, someone in the United States has a stroke about every 40 seconds. This is about 795,000 people per year.

Did you know?

A strange skin disease referred to as Morgellons has occurred in the southern United States and in California. Symptoms include slowly healing sores, joint pain, persistent fatigue, and a sensation of things crawling through the skin. Another symptom is strange-looking, threadlike extrusions coming out of the skin.

Did you know?

Pink eye is a term that refers to conjunctivitis, which is inflammation of the thin, clear membrane (conjunctiva) over the white part of the eye (sclera). It may be triggered by a virus, bacteria, or foreign body in the eye. Antibiotic eye drops alleviate bacterial conjunctivitis, and antihistamine allergy pills or eye drops help control allergic conjunctivitis symptoms.

Did you know?

Critical care patients are twice as likely to receive the wrong medication. Of these errors, 20% are life-threatening, and 42% require additional life-sustaining treatments.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library